心力衰竭防治的新机制与新途径  

Novel mechanisms and approaches for prevention and treatment of heart failure

作　　者：廖玉华[1] 廖梦阳 袁璟[1] LIAO Yuhua;LIAO Mengyang;YUAN Jing(Department of Cardiology,Union Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan,430022,China)

机构地区：[1]华中科技大学同济医学院附属协和医院心内科,武汉430022

出　　处：《临床心血管病杂志》2024年第1期1-4,共4页Journal of Clinical Cardiology

摘　　要：随机临床试验(RCT)结果对心力衰竭(心衰)的病理生理机制提出了挑战,钠-葡萄糖协同转运蛋白-2(SGLT2)抑制剂跨越了神经激素机制对心衰的认识。基于RCT和基础研究证据,本文将探索免疫代谢炎症和心肌细胞信号通路障碍在心衰发病机制中的作用,为心衰防治提供新的靶向治疗方案。Recent results of randomized clinical trials(RCT)pose a challenge to the pathophysiology of heart failure(HF).The positive impact of sodium-glucose co-transporter 2(SGLT-2)inhibitors on HF offers new insight into HF beyond the understanding of neurohormonal mechanisms.Based on current evidence from RCTs and basic researches,in this article,we will explore the role of immunometabolic inflammation and dysfunction of the myocardial cell signaling pathway in the pathogenesis of HF,which would provide a new targeted therapy for HF.

关 键 词：心力衰竭 神经激素 免疫代谢 炎症 细胞信号通路 

分 类 号：R541.6[医药卫生—心血管疾病]